13 rezultātiem
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 filing of PCT International application no. PCT/EP2005/004254 filed Apr. 20, 2005 and published in English as WO 2005/103712 on Nov. 3, 2005 which claims the priority of European application no. 040009284.3 filed Apr. 20, 2004. The
The present invention relates to the use of protachykinin and/or its fragments and/or its splice variants, fragments comprising protachykinin and/or combinations thereof in medical diagnostics. In the following text all these molecules, fragments, combinations thereof etc. are referred to as
This is a national stage application under 35 U.S.C. 371 of PCT/JP2006/312712 filed on Jun. 26, 2006, which claims priority from Japanese patent application 2005-185916 filed on Jun. 27, 2005, all of which are incorporated herein be reference.
TECHNICAL FIELD
The present invention relates to an
The present invention relates to non-natural galanin receptor ligands which can function as agonists and antagonists of galanin and can be used to treat diseases or conditions in which galanin plays a role.
BACKGROUND OF THE INVENTION
Galanin.sup.1 is a 29/30 amino acid long neuroendocrine peptide
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is the US national stage of International Application PCT/IB2007/003784 filed on Dec. 6, 2007 which, in turn, claims priority to European Application 06026533.7, filed on Dec. 21, 2006.
FIELD OF THE INVENTION
The present invention
FIELD OF THE INVENTION
The invention relates to .mu. opioid receptor binding phenylpiperidine compounds. The compounds are useful in conditions or diseases associated with binding opioid receptors, for instance, as analgesics and tardive dyskinesia treatments.
BACKGROUND OF THE INVENTION
Opiates
TECHNICAL FIELD
This invention relates to 2H-phthalazin-1-one derivatives and poly (ADP-ribose) polymerase inhibitors containing 2H-phthalazin-1-one derivatives as active ingredient.
More particularly, this invention relates to poly (ADP-ribose) polymerase inhibitors containing 2H-phthalazin-1-one
TECHNICAL FIELD
The present invention relates to fused pyridazine derivative compounds.
More particularly, the present invention relates to (1) pyridazine derivative compounds represented by formula (I)
##STR00002## (wherein all symbols have the same meanings as described below), or pharmaceutically
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.
FIELD OF THE INVENTION
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions
FIELD OF THE INVENTION
The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that
FIELD OF THE INVENTION
The present invention relates to crystalline forms of (1aS,5aS)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclop- ropa[a]pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that
CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority from and the benefit of Pakistani Patent Application No. 296/2017, filed on May 24, 2017, which is hereby incorporated by reference for all purposes as if fully set forth herein.
BACKGROUND
Field
Exemplary embodiments relate to